TLX vs EXEL vs RNW vs AGEN vs BMY

For growth investors, Telix Pharmaceuticals Limited (TLX) is the stronger pick with 55.

8% revenue growth year-over-year, versus -0. 2% for Bristol-Myers Squibb Company (BMY). Bristol-Myers Squibb Company (BMY) offers the better valuation at 16. 3x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate Telix Pharmaceuticals Limited (TLX) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bristol-Myers Squibb Company (BMY) is the cheapest at 16.

3x versus Telix Pharmaceuticals Limited at 105. 7x. On forward P/E, ReNew Energy Global Plc is actually cheaper at 0. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Exelixis, Inc.

(EXEL) delivered a total return of +93. 0%, compared to -93. 7% for Agenus Inc. (AGEN). Over 10 years, the gap is even starker: EXEL returned +872. 9% versus AGEN's -94. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bristol-Myers Squibb Company (BMY) is the lower-risk stock at 0.

45β versus Agenus Inc. 's 2. 58β — meaning AGEN is approximately 469% more volatile than BMY relative to the S&P 500. On balance sheet safety, Exelixis, Inc. (EXEL) carries a lower debt/equity ratio of 8% versus 6% for ReNew Energy Global Plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Telix Pharmaceuticals Limited (TLX) is pulling ahead at 55.

8% versus -0. 2% for Bristol-Myers Squibb Company (BMY). On earnings-per-share growth, the picture is similar: Telix Pharmaceuticals Limited grew EPS 769. 6% year-over-year, compared to 10. 1% for ReNew Energy Global Plc. Over a 3-year CAGR, TLX leads at 368. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Exelixis, Inc.

(EXEL) is the more profitable company, earning 33. 7% net margin versus 0. 1% for Agenus Inc. — meaning it keeps 33. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RNW leads at 53. 5% versus -18. 0% for AGEN. At the gross margin level — before operating expenses — EXEL leads at 96. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ReNew Energy Global Plc (RNW) trades at 0.

4x forward P/E versus 167. 1x for Telix Pharmaceuticals Limited — 166. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AGEN: 91. 9% to $7. 33.

In this comparison, BMY (4.

4% yield) pays a dividend. TLX, EXEL, RNW, AGEN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Bristol-Myers Squibb Company (BMY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

45), 4. 4% yield). Agenus Inc. (AGEN) carries a higher beta of 2. 58 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BMY: +6. 6%, AGEN: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (TLX (Healthcare) and EXEL (Healthcare) and RNW (Utilities) and AGEN (Healthcare) and BMY (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: TLX is a small-cap high-growth stock; EXEL is a mid-cap deep-value stock; RNW is a small-cap high-growth stock; AGEN is a small-cap quality compounder stock; BMY is a mid-cap deep-value stock. BMY pays a dividend while TLX, EXEL, RNW, AGEN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.